NDA 215498 · Ipsen
Bylvay
Odevixibat · Oral · Ileal Bile Acid Transporter Inhibitor
NovelPriority reviewOrphanCDER novel approval, Jul 20, 2021: To treat pruritus
Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jul 20, 2021
Approved uses
3
Original approval plus efficacy supplements
Registered trials
6
6 Phase 3, 0 recruiting
FAERS reports
398
162 serious, 19 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 29, 2025.
BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 12.5 , 14.1 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 ) 1.1 Progressive Familial Intrahepatic Cholestasis (PFIC) BYLVAY is indicated for the treatment of pruritus in patients 3 months of age and older with PFIC. Limitations of Use BYLVAY is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump (BSEP) protein [see Clinical Pharmacology (12.5) and Clinical Studies (14.1) ]. 1.2 Alagille Syndrome (ALGS) BYLVAY is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with ALGS.
Mechanism: Odevixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum . Pruritus is a common symptom in patients with PFIC and ALGS; the pathophysiology of pruritus in patients with PFIC is not completely understood. Although the complete mechanism by which odevixibat improves pruritus in both PFIC and ALGS patients is unknown, it may involve inhibition of the IBAT, which results in decreased reuptake of bile salts, as observed by a decrease in serum bile acids [see Clinical Pharmacology...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2025 Supplement 5 · Efficacy OrphanLabelLetter
- Jun 13, 2023 Supplement 3 · Efficacy · priority review OrphanLetterLabel
- Jul 20, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
4 products under this application
- BYLVAY · ODEVIXIBAT 1.2MG · CAPSULE, ORAL · Prescription
- BYLVAY · ODEVIXIBAT 0.4MG · CAPSULE, ORAL · Prescription
- BYLVAY · ODEVIXIBAT 0.6MG · CAPSULE, PELLETS, ORAL · Prescription
- BYLVAY · ODEVIXIBAT 0.2MG · CAPSULE, PELLETS, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Odevixibat" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)Pivotal-lookingCompleted
Albireo, an Ipsen CompanyIndustry
NCT04336722 · 254 participants · Start Jul 8, 2020 · Primary completion Jun 22, 2026
Drug: Odevixibat; Placebo · For: Biliary Atresia
Sites: Los Angeles, California; Palo Alto, California; San Diego, California · 72 sites in all
- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaPivotal-lookingActive, not recruiting
Albireo, an Ipsen CompanyIndustry
NCT05426733 · 180 participants (planned) · Start Jul 5, 2022 · Primary completion Oct 28, 2026
Drug: Odevixibat · For: Biliary Atresia
Sites: Aurora, Colorado; Atlanta, Georgia; Indianapolis, Indiana · 30 sites in all
- Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFICPivotal-lookingCompleted
Albireo, an Ipsen CompanyIndustry
NCT03659916 · 116 participants · Start Sep 28, 2018 · Primary completion Feb 15, 2024
Drug: A4250 (odevixibat) · For: Progressive Familial Intrahepatic Cholestasis
Sites: Los Angeles, California; Denver, Colorado; Atlanta, Georgia · 41 sites in all
- This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2Pivotal-lookingCompleted
AlbireoIndustry
NCT03566238 · 62 participants · Start May 16, 2018 · Primary completion Jul 27, 2020
Drug: A4250 (odevixibat); Placebo · For: PFIC1; PFIC2
Sites: Los Angeles, California; San Francisco, California; Denver, Colorado · 45 sites in all
- Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromePivotal-lookingActive, not recruiting
Albireo, an Ipsen CompanyIndustry
NCT05035030 · 62 participants · Start Sep 3, 2021 · Primary completion Feb 15, 2027
Drug: Odevixibat · For: Alagille Syndrome
Sites: San Diego, California; San Francisco, California; Atlanta, Georgia · 35 sites in all
- Efficacy and Safety of Odevixibat in Patients With Alagille SyndromePivotal-lookingCompleted
AlbireoIndustry
NCT04674761 · 52 participants · Start Mar 19, 2021 · Primary completion Sep 9, 2022
Drug: Odevixibat; Placebo · For: Alagille Syndrome
Sites: San Francisco, California; Baltimore, Maryland; Boston, Massachusetts · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pruritus106
- diarrhoea99
- off label use79
- drug ineffective39
- liver transplant36
- product dose omission issue27
- abdominal pain upper25
- hepatic enzyme increased25
- abdominal pain22
- blood bilirubin increased22
- alanine aminotransferase increased20
- bile acids increased20
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 4 |
| 2022 | 52 |
| 2023 | 48 |
| 2024 | 60 |
| 2025 | 107 |
| 2026 | 127 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bylvay (Odevixibat)
2024 spending
$6.4M
Beneficiaries
n/a
52 claims
Per beneficiary
n/a
$990.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,258,158 |
| 2023 | $3,312,672 |
| 2024 | $6,404,368 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
Thompson RJ, Arnell H, Artan R, et al. · Lancet Gastroenterol Hepatol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.
Ovchinsky N, Aumar M, Baker A, et al. · Lancet Gastroenterol Hepatol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
Baumann U, Sturm E, Lacaille F, et al. · Clin Res Hepatol Gastroenterol 2021 · Clinical Trial, Phase II, Multicenter Study
- Positive phase III results for odevixibat for progressive familial intrahepatic cholestasis.
Ray K · Nat Rev Gastroenterol Hepatol 2022 · Clinical Trial, Phase III
- Ileal bile acid transporter inhibitors in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis: A systematic review into dose-response.
de Groot ADE, Chiadò C, Kosterink JGW, et al. · Br J Clin Pharmacol 2026 · Systematic Review
- Efficacy of ileal bile acid transport inhibitors in children with Alagille syndrome: a meta-analysis.
Lopes JR, Esteves IM, Libonati NB, et al. · Eur J Pediatr 2025 · Meta-Analysis, Review
Sponsor: Ipsen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.